Fig. 1: Identification of the potential biomarker for breast cancer neoadjuvant chemotherapy.
From: FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction
a Identification of patients with breast cancer who underwent neoadjuvant chemotherapy as primary treatment in the Sichuan cancer center in China between 2017 and 2019. b, c Clinical evaluation of pathological downstaging of T (tumor) and TN (tumor, Lymph Node) stages based on molecular classification. d A set of representative MRI images of the favorable and poor effect of NACT for breast cancer treatment is shown. e Data analysis and mining from the data resources GSE25066 to find the relevant genes of neoadjuvant chemotherapy effect. f, g Gene expression analysis and gene ontology enrichment were performed to find the top relevant genes of neoadjuvant chemotherapy effect. h Survival analysis of breast cancer patients with neoadjuvant chemotherapy to the expression of FZR1 in the database of KMPLOT.
